Moderator : Xiaofei Jiang, Fadong Chen
Discussant : Wei Sun, Song Yang
08:10-08:25 Evidence-based practice of LAAC Daxin Zhou
08:25-08:40 Design feature and key application technique of different types of LAA occluder Xi Su
08:40-08:55 Assessment and management of residual leak after LAAC Jiangui He
08:55-09:00 Discussion
09:00-09:30 Live case--Nanjing First Hospital (LACC) Xiaochun Zhang
09:00-09:30 Live case--Nanjing First Hospital (LACC) Gaofeng Wang
09:30-10:00 Live case--Nanjing First Hospital (LACC) Dujiang Xie
09:30-10:00 Live case--Nanjing First Hospital (LACC) Jie Luo
Chair : Shao-Liang Chen, Junjie Zhang
Moderator : Kai Xu, Jing Chen, Xiang Chen
08:30-08:35 Welcoming Speech & SAPIEN3 COE Awarding Junjie Zhang
08:35-08:55 Evidence based Treatment of TAVR:From prohibitive risk to lower risk and beyond Jiancheng Zhu
08:55-09:00 Discussion Jinpeng Xu, Jun Ji
09:00-09:20 心动图评估主动脉瓣病变应用要点 Yan Liu
09:20-09:25 Discussion Juan Zhang, Yueming Wu
09:25-09:45 Balloon Expandable Valve Procedure- Step by Step Xiangquan Kong
09:45-09:50 Discussion Bing Xu, Xiaodong Qian
09:50-10:10 Patient Management Of TAVR during perioeration Zhimei Wang
10:10-10:15 Discussion Koulong Zheng
10:15-10:25 SAPIEN 3 Experience in Nanjing First Hospital Junjie Zhang
10:25-10:30 Discussion Xiaoyu Yang
Moderator : Gary S. Mintz, Ricardo Costa, Bin Liu
Discussant : Duk-Woo Park, Tak W Kwan, Robert Julian Gil, Jie Qian, Tzung-Dau Wang, Ning Guo, Ho Lam, Qinhua Jin, Liansheng Wang
08:30-08:43 What did we learn from the OCTOBER trial? Niels Ramsing Holm
08:43-08:48 Discussion
08:48-09:01 OCTIVUS trial Duk-Woo Park
09:01-09:06 Discussion
09:06-09:19 IVUS vs OCT, Can Intravascular Imaging Detect Vulnerable Plaque and, if so, Does it Make Sense to Try? Gary S. Mintz
09:19-09:24 Discussion
09:23-10:40 Live case 15--Nanjing First Hospital Tao Pan
09:24-10:40 Live case 15--Nanjing First Hospital Mamas A. Mamas
09:24-10:40 Live case 16--Nanjing First Hospital Muhammad Munawar
09:24-10:40 Live case 15--Nanjing First Hospital Mingxue Shao
09:24-10:40 Live case 16--Nanjing First Hospital Zhiming Wu
09:24-10:40 Live case 16--Nanjing First Hospital Chengfeng GUAN
Moderator : Jie Wang
Discussant : Pingjin Gao, Yueping Li, Linlin Zhu, Junxia Zhang
08:40-08:55 Compliance and reasonable drug intervention in the treatment of refractory hypertension Ningling Sun
08:55-09:00 Discussion
09:00-09:15 How to implement the integrated management of Yingqing Feng
09:15-09:20 Discussion
09:20-09:35 The target for blood pressure lowering—-Evidence and Strategy Zhao Li
09:35-09:40 Discussion
09:40-09:55 Innovation and development in pharmacologic treatments of hypertension Yuqing Zhang
09:55-10:00 Discussion
10:00-10:10 Conclusion and Session Summary
Moderator : Shao-Liang Chen, Lan Hieu Nguyen, Haibo Hu, Yuan Bai
Discussant : Cheng Wang, Lei Wang, Qing Mao
10:10-10:25 Recent research progress of PFO Yushun Zhang
10:25-10:40 Selection of occluders based on ultrasound parameters in PFO closure Caojin Zhang
10:40-10:55 Complications associated with PFO closure Gangcheng Zhang
10:55-11:10 Transcatheter closure of VSD (My experiences) Lan Hieu Nguyen
11:10-11:15 Discussion
11:15-12:00 Live case--Nanjing First Hospital (PFO) Xiaochun Zhang
11:15-12:00 Live case--Nanjing First Hospital (PFO) Dujiang Xie
11:15-12:00 Live case--Nanjing First Hospital (PFO) Gaofeng Wang
11:15-12:00 Live case--Nanjing First Hospital (PFO) Jie Luo
Moderator : Ningling Sun
Discussant : Yuqing Zhang, Zhao Li, Hang Zhang, Linlin Zhu, Weichun Qian
10:30-10:45 Chinese expert consensus on management of salt-sensitive hypertension Yuming Li
10:45-10:50 Discussion
10:50-11:05 Progress in RDN treatment of hypertension: Netrod study Yueping Li
11:05-11:10 Discussion
11:10-11:25 The application of intervention techniques beyond RDN in hypertension Pingjin Gao
11:25-11:30 Discussion
11:30-11:45 Sympathetic mapping/ablation renal nerves for treatment of hypertension: SMART study Jie Wang
11:45-11:50 Discussion
11:50-12:00 Conclusion and Session Summary
Moderator : Imad Sheiban, Dongming Hou
Discussant : Leif Thuesen, Afsar Raza, Ayman A. Magd, Francesco Lavarra, Bill D. Gogas, Jinpeng Wang, Jun Zhang
10:45-10:58 ORBITA 2: Findings & limitations Ayman A. Magd
10:58-11:03 Discussion
11:03-11:16 IVUS or OCT is the gold standard intravascular imaging in Bifurcation interventions ? Imad Sheiban
11:16-11:21 Discussion
11:21-11:34 Angiography-Derived FFR for Bifurcation Lesion: Current and Future Shengxian Tu
11:34-11:39 Discussion
11:39-11:49 How Can FFR Affect the Treatment of the Patient? Case Vignettes Afzalur Rahman
11:49-11:52 Discussion
11:52-12:50 Live case 17--Nanjing First Hospital Gerald S. Werner
11:52-12:50 Live case 18--Nanjing First Hospital Vladimir Džavík
11:52-12:50 Live case 18--Nanjing First Hospital Niels Ramsing Holm
11:52-12:50 Live case 17--Nanjing First Hospital Xiaofei Gao
11:52-12:50 Live case 18--Nanjing First Hospital Tao Pan
11:52-12:50 Live case 18--Nanjing First Hospital Yunfei Deng
Moderator : Shao-Liang Chen, Yuqing Hou, Liansheng Wang, Xiaoxia Fu
13:00-13:10 Video of the 50th anniversary of the Chinese Journal of Cardiology
13:10-13:25 Interpretation of “Chinese guideline for percutaneous coronary intervention in patients with left main bifurcation disease” Shao-Liang Chen
13:25-13:35 Discussion
13:35-13:50 Interpretation of “Chinese expert consensus on microvascular protection strategy during emergency PCI therapy in patients with ST-elevation myocardial infarction” Muwei Li
13:50-14:00 Discussion
14:00-14:15 Interpretation of “Chinese expert consensus on diagnosis and management on patients with ischemia and non-obstructive coronary artery disease” Ning Guo
14:15-14:25 Discussion
14:25-14:40 Interpretation of “Chinese guidelines for lipid management (2023)” Jianping Li
14:40-14:50 Discussion
14:50-15:05 Interpretation of “Chinese expert consensus on the diagnosis and treatment of pulmonary vein stenosis” Ben He
15:05-15:15 Discussion
15:15-15:30 Interpretation of “ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'” Xinli Li
15:30-15:40 Discussion